A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Recruiting

Phase 2

Phase 3

Islatravir & UlonivirineA Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT07266831

Conditions

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ISL

ULO

BIC/FTC/TAF

Placebo for BIC/FTC/TAF

Placebo to ISL/ULO

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-02. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-12-17.